Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
Oncotarget · 2023
DOI: 10.18632/oncotarget.28458 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Oncotarget, 2023. Verfasst von Devalingam Mahalingam und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Metformin, Metabolic Syndrome, Insulins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA.
- Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
- Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
- Institute for Drug Development, Mays Cancer Center at University of Texas Health, San Antonio, TX 78229, USA.
- Audie Murphy VA Hospital, San Antonio, TX 78229, USA.
- Division of Experimental Medicine, Lady Davis Institute of Medical Research, Jewish General Hospital, McGill University, Montreal, Canada.
Förderung
- NCI NIH HHS
Zitieren
APA
Mahalingam, D., Hanni, S., Serritella, A. V., Fountzilas, C., Michalek, J., Hernandez, B., Sarantopoulos, J., Datta, P., Romero, O., Pillai, S. M. A., Kuhn, J., Pollak, M., & Thompson, I. M. (2023). Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer. Oncotarget. https://doi.org/10.18632/oncotarget.28458
Vancouver
Mahalingam D, Hanni S, Serritella AV, Fountzilas C, Michalek J, Hernandez B, et al. Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer. Oncotarget. 2023. doi:10.18632/oncotarget.28458
BibTeX
@article{Mahalingam2023,
author = {Mahalingam, Devalingam and Hanni, Salih and Serritella, Anthony V and Fountzilas, Christos and Michalek, Joel and Hernandez, Brian and Sarantopoulos, John and Datta, Paromitta and Romero, Ofelia and Pillai, Sureshkumar Mulampurath Achutan and Kuhn, John and Pollak, Michael and Thompson, Ian M},
title = {Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer},
journal = {Oncotarget},
year = {2023},
doi = {10.18632/oncotarget.28458}
}
EUVIMED